FDA Extends Approval for Alirocumab to Lower LDL-C in Pediatric Patients with HeFH 

Addressing an Unmet Need in Pediatric Patients with HeFH  Heterozygous familial hypercholesterolemia (HeFH) affects about 1 in 313 people—characterized by dangerously high low-density lipoprotein cholesterol (LDL-C) levels. Untreated, it can trigger early heart disease. Detecting and treating it early in pediatric patients can prevent heart problems later. American College of Cardiology/American Heart Association guidelines define acceptable LDL-C […]

FDA Expands Labels for Bempedoic Acid Tablets and Combination Bempedoic Acid and Ezetimibe Tablets to Reduce Cardiovascular Risk 

Introduction: Addressing the Need for Improved LDL Management in the US  There is a clear need for innovative treatments to combat cardiovascular disease (CVD).  Heart disease remains the leading cause of death for men and women. 80% of heart attacks and strokes linked to CVD are preventable with optimal risk factor management. However, every 40 seconds, an individual […]

Exploring Obesity and the Latest Advances in Weight Loss Drugs during Healthy Weight Week

weight loss drugs

In today’s society, the prevalence of obesity has become a significant concern. With sedentary lifestyles and the easy availability of unhealthy food choices, more and more individuals are struggling with weight-related issues. This has led to a growing recognition of the importance of maintaining a healthy weight and taking proactive steps towards achieving it. Currently, […]

ACC/AHA Release Updated 2023 Guidelines for Atrial Fibrillation

atrial fibrillation

The American College of Cardiology (ACC) and the American Heart Association (AHA) recently published new guidelines for the diagnosis and management of patients with atrial fibrillation (AF). These new guidelines provide necessary updates to both the 2014 AHA/ACC/HRS Guideline for the Management of Patients With Atrial Fibrillation and the 2019 AHA/ACC/HRS Focused Update of the […]